Knockin

Knockin describes targeted insertion of specific genetic sequences into a defined genomic location, enabling introduction of mutations, reporter genes, humanised sequences, or therapeutic constructs while preserving genomic context. Unlike random transgenesis, knockin approaches provide precise genetic modification, often achieved through homologous recombination or CRISPR-based editing. Knockin models allow controlled investigation of disease mutations, protein function, and gene regulation under physiologically relevant expression patterns.

The biopharmaceutical industry employs knockin systems for disease modelling, target validation, and evaluation of therapeutic strategies. Knockin mice carrying human disease mutations replicate clinically relevant biology, supporting testing of targeted therapies and biomarker development. Humanised knockin models replace murine sequences with human counterparts, improving relevance for antibody therapies and immunology research. Manufacturing cell lines may use knockin strategies to integrate expression constructs into stable genomic sites, improving productivity and consistency. As genome engineering becomes increasingly efficient through CRISPR technologies, knockin approaches expand through improved precision, scalability, and relevance supporting translational research and therapeutic development.